BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Australia

Data4Life, Monash Health Partner to Accelerate Clinical Trials and Real-World Evidence Generation

Data4Life and Monash Health have partnered to optimize clinical trial design and execution, complemented by educational workshops and professional training...

September 01, 2026 | News

SIBIONICS Showcases AI-Powered GS3 Glucose Monitoring, Advances Integrated Diabetes Care at Melbourne Congress

SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbour...

September 01, 2026 | News

ReviR Therapeutics’ RTX-117 Secures FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth Disease

Designation supports the global development of RTX-117 and may provide potential future access to a transferable Priority Review Voucher, subject to approv...

August 28, 2026 | News

HaemaLogiX Doses First Patient with KMCAR T-Cell Therapy in Phase 1 Multiple Myeloma Trial

First patient safely dosed in Phase 1 KOALA trial evaluating KMCAR™ T-cell therapy in patients with relapsed/refractory kappa-restricted multiple m...

August 27, 2026 | News

WuXi XDC H1 2026 Revenue Jumps 37% to RMB 3.7 Bn on Strong Bioconjugate Demand

Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2]...

August 26, 2026 | Company results

Antengene’s ATG-201 Wins Australian Clearance for Phase I Autoimmune Disease Trial

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

August 26, 2026 | News

CureGene Doses First Subject in Australia Phase I Trial of Oral Metabolic Drug CG-0416

CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist...

August 24, 2026 | News

ArkBio’s Long-Acting Influenza Candidate AK0406 Secures IND Approval in China

Shanghai Ark Biopharmaceutical Co., Ltd. announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-actin...

August 14, 2026 | News

Australians Warned Against Buying Unregulated Health Supplements from Overseas

With longevity science gaining global attention and new products rapidly entering the market, overseas supplement retailers are increasingly targeting Aust...

August 06, 2026 | News

IMPACT Therapeutics Partners with Pharmanovia to Commercialise Senaparib Across Europe, MENA, Australia and New Zealand

IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharm...

August 03, 2026 | News

7 Countries Competing to Be the Region’s Next Biomanufacturing Hub

A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...

July 27, 2026 | Analysis

ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...

July 27, 2026 | News

Menarini Asia-Pacific, Pharmacosmos Partner to Expand Cosela® Access Across APAC

Menarini Asia-Pacific announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela® (trilaciclib) acr...

July 23, 2026 | News

Dimerix Acquires Phase II-Ready DMX-652 to Expand Kidney Disease Pipeline

Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New D...

July 20, 2026 | News

Stay Connected